- Pharma Industry
- 1 min read
Lupin receives US FDA approval for Eslicarbazepine Acetate Tablets
Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.
Mumbai: Lupin Limited announced that it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, to market a generic equivalent of Aptiom Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, of Sumitomo Pharma America, Inc. Lupin is one of the first ANDA applicants and may be eligible for 180 days of shared generic exclusivity. The product will be manufactured at Lupin’s Pithampur facility in India.
Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.
Eslicarbazepine Acetate Tablets (RLD Aptiom) had estimated annual sales of $354 million in the US (IQVIA MAT January 2024).
Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.
Eslicarbazepine Acetate Tablets (RLD Aptiom) had estimated annual sales of $354 million in the US (IQVIA MAT January 2024).
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions